Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Angiogenesis Inhibitors
/ therapeutic use
Chemoradiotherapy
/ methods
Female
Genital Neoplasms, Female
/ drug therapy
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
/ methods
Lung Neoplasms
/ drug therapy
Melanoma
/ drug therapy
Skin Neoplasms
/ drug therapy
Uterine Cervical Neoplasms
/ drug therapy
Melanoma, Cutaneous Malignant
cervical cancer
chemoradiotherapy
immune checkpoint inhibitor
immunotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Mar 2020
27 Mar 2020
Historique:
received:
27
02
2020
revised:
24
03
2020
accepted:
25
03
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
6
1
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have demonstrated marked clinical effects worldwide, and "cancer immunotherapy" has been recognized as a feasible option for cancer treatment. Significant treatment responses have already been attained for malignant melanoma and lung cancer, ahead of gynecologic cancer. In cervical cancer, however, results are only available from phase II trials, not from phase III trials. Cervical cancer is a malignant tumor and is the fourth most common cancer among women worldwide. Since the introduction of angiogenesis inhibitors, treatment for recurrent and advanced cervical cancers has improved in the past five years, but median overall survival is 16.8 months for advanced cervical cancer, and all-stage five-year overall survival rate is 68%, indicating that treatment effects remain inadequate. For this reason, the development of new therapeutic approaches is imperative. We describe herein the KEYNOTE-158 and CheckMate 358 clinical trials, which were conducted for cervical cancer, and discuss future directions, including potential combinations with concurrent chemoradiation therapy (CCRT), as noted for other types of cancer.
Identifiants
pubmed: 32230938
pii: ijms21072335
doi: 10.3390/ijms21072335
pmc: PMC7177858
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Mod Pathol. 2017 Apr;30(4):577-586
pubmed: 28059093
Mod Pathol. 2015 Dec;28(12):1594-602
pubmed: 26403783
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Lancet. 2019 Jun 15;393(10189):2404-2415
pubmed: 31079938
Oncoimmunology. 2014 Apr 25;3:e28518
pubmed: 25071979
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Int Immunol. 2016 Aug;28(8):393-9
pubmed: 27401477
Mol Med Rep. 2017 Mar;15(3):1063-1070
pubmed: 28075442
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Gynecol Oncol. 2019 Jul;154(1):236-245
pubmed: 30995960
J Biomed Sci. 2017 Apr 4;24(1):26
pubmed: 28376884
JAMA Oncol. 2016 Nov 1;2(11):1490-1495
pubmed: 27491050
Int J Gynecol Cancer. 2020 Jan;30(1):139-143
pubmed: 31645423
J Clin Oncol. 2019 Nov 1;37(31):2825-2834
pubmed: 31487218
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Clin Oncol. 2017 Dec 20;35(36):4035-4041
pubmed: 29095678
Cancer Manag Res. 2018 Jan 18;10:105-113
pubmed: 29403308
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Clin Cancer Res. 2018 Mar 15;24(6):1271-1276
pubmed: 29358503
N Engl J Med. 2014 Feb 20;370(8):734-43
pubmed: 24552320
Diagn Pathol. 2017 Jun 17;12(1):45
pubmed: 28623908
Int Immunol. 2016 Jul;28(7):339-48
pubmed: 27055470
Anticancer Res. 2007 Jan-Feb;27(1B):499-503
pubmed: 17348433
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Front Immunol. 2012 Feb 23;3:21
pubmed: 22566905
J Cancer. 2018 Jul 30;9(16):2938-2945
pubmed: 30123362
Trends Immunol. 2018 Aug;39(8):644-655
pubmed: 30001871
Curr Probl Cancer. 2016 Jan-Feb;40(1):25-37
pubmed: 26582738
Oncoimmunology. 2017 Feb 6;6(3):e1288331
pubmed: 28405521
Healthcare (Basel). 2019 Sep 17;7(3):
pubmed: 31533297